Unknown

Dataset Information

0

Prevalence of Hepatitis B Vaccination Coverage and Serologic Evidence of Immunity Among US-Born Children and Adolescents From 1999 to 2016.


ABSTRACT: Importance:The World Health Assembly has called for the elimination of hepatitis B and C by 2030. As hepatitis B has no cure, the US strategy to eliminate hepatitis B has focused on prevention through vaccination. However, there are limited data on the trend in vaccine-associated immunity since the US implementation of universal infant hepatitis B vaccination. Objective:To compare self-reported hepatitis B vaccination coverage among children and adolescents with serologic evidence of immunity and infection in the US from 1999 to 2016. Design, Setting, and Participants:This population-based cross-sectional study used data from the National Health and Nutrition Examination Survey (NHANES) from 1999 to 2016. US-born persons aged 2 to 18 years without missing hepatitis B serologic test results and with reported vaccination history were included. Data were analyzed from September 2017 to June 2018. Main Outcomes and Measures:The proportion of participants who reported complete vaccination for hepatitis B and who had positive serologic test results indicating immunity. Results:Of 21?873 children and adolescents, 51.2%% were male, and the mean (SD) age was 10.6 (4.6) years. The survey reported that hepatitis B vaccination coverage increased significantly from 1999 to 2016 (from 62.6% [95% CI, 58.6%-66.4%] to 86.3% [95% CI, 82.9%-89.2%]; P?

SUBMITTER: Le MH 

PROVIDER: S-EPMC7658733 | biostudies-literature | 2020 Nov

REPOSITORIES: biostudies-literature

altmetric image

Publications

Prevalence of Hepatitis B Vaccination Coverage and Serologic Evidence of Immunity Among US-Born Children and Adolescents From 1999 to 2016.

Le Michael H MH   Yeo Yee Hui YH   So Samuel S   Gane Ed E   Cheung Ramsey C RC   Nguyen Mindie H MH  

JAMA network open 20201102 11


<h4>Importance</h4>The World Health Assembly has called for the elimination of hepatitis B and C by 2030. As hepatitis B has no cure, the US strategy to eliminate hepatitis B has focused on prevention through vaccination. However, there are limited data on the trend in vaccine-associated immunity since the US implementation of universal infant hepatitis B vaccination.<h4>Objective</h4>To compare self-reported hepatitis B vaccination coverage among children and adolescents with serologic evidence  ...[more]

Similar Datasets

| S-EPMC9506316 | biostudies-literature
| S-EPMC6109602 | biostudies-literature
| S-EPMC9016947 | biostudies-literature
| S-EPMC8364709 | biostudies-literature
| S-EPMC6755034 | biostudies-literature
| S-EPMC7661536 | biostudies-literature
| S-EPMC6504080 | biostudies-literature
| S-EPMC6063734 | biostudies-literature
| S-EPMC6332691 | biostudies-literature
| S-EPMC6286230 | biostudies-literature